Metabolic
Tirzepatide
Mounjaro · Zepbound · GIP/GLP-1 · dual agonist
A licensed dual-pathway weight-loss and diabetes medicine with some of the strongest trial results in this entire library — a genuine prescription medicine, not a research chemical.
Reference status
Editorial research · independent review pending · 3 claims graded
What it is
Tirzepatide acts on both the GIP and GLP-1 receptors, and its phase-3 trials (SURMOUNT for weight, SURPASS for diabetes) produced some of the largest average weight-loss figures seen in this drug class to date. It's a licensed medicine (Mounjaro / Zepbound) in the UK and elsewhere.
As with semaglutide, we include it because people search for it alongside 'peptides' — but it belongs in the prescription-medicine lane, not the research-chemical one. Unlicensed 'research tirzepatide' carries the same sourcing and quality risks as unlicensed semaglutide.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Produces substantial weight loss”
SURMOUNT trials show average losses exceeding those seen with semaglutide in head-to-head-style comparisons.
Claim-level citation mapping is in progress.
“Improves blood-sugar control in type-2 diabetes”
Core licensed indication, backed by the SURPASS trial programme.
Claim-level citation mapping is in progress.
“Safe to self-source and self-dose without supervision”
A real medicine with real side effects and dosing complexity — needs proper medical supervision.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Prescription-only medicine (POM) in the UK, available via GPs and regulated weight-management/diabetes services. Buying unlicensed 'research' tirzepatide is unsafe and outside the law.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
Discussion increasingly rivals semaglutide's, often framed as 'the stronger option'. Same split as semaglutide between legitimate prescription users and grey-market research-labelled sourcing.
Where they’re talking
- News & socialHigh-profile coverage alongside semaglutide.
- r/TirzepatidePrescription users compare dosing and side-effect timelines.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Buying medicines online · European Medicines Agency